blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3226866

EP3226866 - ATRIAL SPECIFIC ANTIARRHYTHMICS FOR USE IN TREATING OR PREVENTING ATRIAL FIBRILLATION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  28.06.2019
Database last updated on 08.10.2024
FormerRequest for examination was made
Status updated on  08.09.2017
FormerThe international publication has been made
Status updated on  30.06.2017
Most recent event   Tooltip28.06.2019Application deemed to be withdrawnpublished on 31.07.2019  [2019/31]
Applicant(s)For all designated states
Tufts Medical Center, Inc.
750 Washington Street
Boston, MA 02111 / US
[2017/41]
Inventor(s)01 / NOUJAIM, Sami
18766 Burndall Court
Land O Lakes, FL 34638 / US
02 / KARAS, Richard H.
100 Populatic Street
Franklin, MA 02038 / US
 [2017/41]
Representative(s)Brantsandpatents bv
Pauline Van Pottelsberghelaan 24
9051 Ghent / BE
[N/P]
Former [2017/41]Brantsandpatents bvba
Pauline Van Pottelsberghelaan 24
9051 Ghent / BE
Application number, filing date15865367.502.12.2015
[2017/41]
WO2015US63457
Priority number, dateUS201462086505P02.12.2014         Original published format: US 201462086505 P
[2017/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016090009
Date:09.06.2016
Language:EN
[2016/23]
Type: A1 Application with search report 
No.:EP3226866
Date:11.10.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 09.06.2016 takes the place of the publication of the European patent application.
[2017/41]
Search report(s)International search report - published on:US09.06.2016
(Supplementary) European search report - dispatched on:EP22.06.2018
ClassificationIPC:A61K31/4706, A61P9/06, A61K45/06
[2018/30]
CPC:
A61K31/4706 (EP,US); A61K45/06 (EP,US); A61P9/06 (EP,US)
Former IPC [2017/41]A61K31/4706, A61P9/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/41]
TitleGerman:VORHOFSPEZIFISCHE ANTIARRHYTHMIKA ZUR VERWENDUNG BEI DER BEHANDLUNG UND VORBEUGUNG VON VORHOFFLIMMERN[2017/41]
English:ATRIAL SPECIFIC ANTIARRHYTHMICS FOR USE IN TREATING OR PREVENTING ATRIAL FIBRILLATION[2017/41]
French:ANTIARYTHMIQUES SPÉCIFIQUES AURICULAIRES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT OU LA PRÉVENTION DE LA FIBRILLATION AURICULAIRE[2017/41]
Entry into regional phase29.06.2017National basic fee paid 
29.06.2017Search fee paid 
29.06.2017Designation fee(s) paid 
29.06.2017Examination fee paid 
Examination procedure29.06.2017Examination requested  [2017/41]
29.06.2017Date on which the examining division has become responsible
18.01.2018Amendment by applicant (claims and/or description)
22.01.2019Application deemed to be withdrawn, date of legal effect  [2019/31]
01.03.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2019/31]
Fees paidRenewal fee
27.12.2017Renewal fee patent year 03
31.12.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]US2013143858  (BOSTROM JONAS [SE], et al) [X] 1,2,6 * paragraph [0498] - paragraph [0503] * [Y] 3,4,8-12
 [XY]  - SAMI F. NOUJAIM ET AL, "Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets", THE FASEB JOURNAL, US, (20101101), vol. 24, no. 11, doi:10.1096/fj.10-163246, ISSN 0892-6638, pages 4302 - 4312, XP055482673 [X] 1,2,6 * abstract * * page 4305, column 1 - column 2 * * figures 3, 5 * * page 4304, column 2 * [Y] 3-5,7-14

DOI:   http://dx.doi.org/10.1096/fj.10-163246
 [X]  - HASHIMOTO N ET AL, "Tertiapin, a selective IK"A"C"h blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 54, no. 2, doi:10.1016/J.PHRS.2006.03.021, ISSN 1043-6618, (20060801), pages 136 - 141, (20060801), XP024907856 [X] 1,2,6 * abstract * * page 138 - page 141 *

DOI:   http://dx.doi.org/10.1016/j.phrs.2006.03.021
 [X]  - URSULA RAVENS ET AL, "Atrial selectivity of antiarrhythmic drugs : Atrial selectivity of antiarrhythmic drug action", THE JOURNAL OF PHYSIOLOGY, GB, (20130712), vol. 591, no. 17, doi:10.1113/jphysiol.2013.256115, ISSN 0022-3751, pages 4087 - 4097, XP055481705 [X] 1,2,6 * abstract * * page 4092 - page 4093 *

DOI:   http://dx.doi.org/10.1113/jphysiol.2013.256115
 [Y]  - PATRICK AUGUSTIJNS ET AL, "Stereoselective Pharmacokinetic Properties of Chloroquine and De-Ethyl-Chloroquine in Humans :", CLINICAL PHARMACOKINETICS., NZ, (19930301), vol. 24, no. 3, doi:10.2165/00003088-199324030-00007, ISSN 0312-5963, pages 259 - 269, XP055482963 [Y] 5,7,13,14 * abstract * * page 260, column 2 * * table 4 * * page 266 - page 267 * * page 268, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.2165/00003088-199324030-00007
International search[XY]US2013143858  (BOSTROM JONAS [SE], et al) [X] 1-3, 7-10, 18 * para [0001];[0018];[0502];[0515]-[0517];[0531] * [Y] 4-6, 11-17, 23-35;
 [Y]US2013296237  (KASTAN MICHAEL B [US], et al) [Y] 14-17, 19-26, 35 * para [0028] ;[0029];[0078] *;
 [Y]US2006014786  (RAUT RAJEEV [IN]) [Y] 13, 21, 34 * para [0054];[0055];[0083] *
 [Y]  - DURATE et al., "Chloroquine Effect on Human Atrial Action Potential under Normal Conditions and during Paroxysmal and Chronic Atrial Fibrillation.", A Simulation Study in 2013 PAN AMERICAN HEALTH CARE EXCHANGES (PAHCE). CONFERENCE, WORKSHOPS, AND EXHIBITS., (20130000), doi:doi:10.1109/PAHCE.2013.6568230, pages 1 - 5, XP032442389 [Y] 4-6, 11-17, 19-35 * . abstract; pg 1, Col 1, para 5 *

DOI:   http://dx.doi.org/10.1109/PAHCE.2013.6568230
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.